StockData
AbCellera Biologics Inc. logo

AbCellera Biologics Inc. (ABCL) stock

ABCLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30172% above fair value
$11.02−0.01 (-0.09%)

Close on Nov 18, 2026Market cap $3.38BP/E –Yield –

Earnings

AbCellera Biologics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 23, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$10.60M
+17.8% on a year earlier
EPS, Q3 FY2026
-$0.13
-$0.19 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of AbCellera Biologics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 23, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 9, 2026after the close$10.60M+17.8%-$0.13Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026during market hours$4.10M-76.0%-$0.18Release
Q1 FY2026ended Mar 31, 2026May 11, 2026during market hours$8.30M+97.6%-$0.14Release
Q4 FY2025ended Dec 31, 2025Feb 24, 2026during market hours$44.90M+780.4%-$0.03Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025during market hours$9.00M+38.5%-$0.19Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025during market hours$17.10M+134.2%-$0.12Release
Q1 FY2025ended Mar 31, 2025May 8, 2025during market hours$4.20M-58.0%-$0.15Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025during market hours$5.10M-44.6%-$0.12Release
Q3 FY2024ended Sep 30, 2024Nov 4, 2024during market hours$6.50M-1.5%-$0.17Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024during market hours$7.30M-27.7%-$0.13Release
Q1 FY2024ended Mar 31, 2024May 7, 2024during market hours$10.00M-18.0%-$0.14Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

AbCellera Biologics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When AbCellera Biologics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases AbCellera Biologics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. News
  4. Update
  5. Update
  6. News
  7. Results
  8. Results
  9. News
  10. News
  11. Results
  12. Results
  13. Results
  14. Results
  15. Update

See a number that looks wrong?